Thomas Jefferson University

Jefferson Digital Commons
Department of Medical Oncology Faculty
Papers

Department of Medical Oncology

7-23-2021

Standardizing
Definitions of Hematopoietic Recovery, Graft
Follow this and additional works at: https://jdc.jefferson.edu/medoncfp
Rejection,
Graft Commons
Failure, Poor Graft Function, and Donor Chimerism
Part of the Oncology

Let
us knowHematopoietic
how access to
this
document benefits
in Allogeneic
Cell
Transplantation:
A Reportyou
on
Behalf of the American Society for Transplantation and Cellular
Recommended Citation
Therapy.
Kharfan-Dabaja, Mohamed A.; Kumar, Ambuj; Ayala, Ernesto; Aljurf, Mahmoud; Nishihori, Taiga;
Marsh, Rebecca; Burroughs, Lauri M.; Majhail, Navneet; Al-Homsi, A. Samer; Al-Kadhimi, Zaid S.;
Mohamed A. Kharfan-Dabaja
Bar, Merav;
Mayo
Clinic Bertaina, Alice; Boelens, Jaap J.; Champlin, Richard; Chaudhury, Sonali; DeFilipp,
Zachariah; Dholaria, Bhagirathbhai; El-Jawahri, Areej; Fanning, Suzanne; Fraint, Ellen; Gergis,
Ambuj Kumar
Usama; Giralt, Sergio; Hamilton, Betty K.; Hashmi, Shahrukh K.; Horn, Biljana; Inamoto, Yoshihiro;
University of South Florida
Jacobsohn, David A.; Jain, Tania; Johnston, Laura; Kanate, Abraham S.; Kansagra, Ankit; Kassim,
Ernesto Ayala
Adetola;
Kean, Leslie S.; Kitko, Carrie L.; Knight-Perry, Jessica; Kurtzberg, Joanne; Liu, Hien;
Mayo
Clinic
MacMillan, Margaret L.; Mahmoudjafari, Zahra; Mielcarek, Marco; Mohty, Mohamad; Nagler,
Arnon;
Nemecek,
Mahmoud
Aljurf Eneida; Olson, Timothy S.; Oran, Betul; Perales, Miguel-Angel; Prockop, Susan
King
Faisal Specialist
Hospital
andIskra;
Research
Centre
E.; Pulsipher,
Michael
A.; Pusic,
Riches,
Marcie L.; Rodriguez, Cesar; Romee, Rizwan;
Rondon, Gabriela; Saad, Ayman; Shah, Nina; Shaw, Peter J.; Shenoy, Shalini; Sierra, Jorge; Talano,
Taiga Nishihori
Julie;
Michael R.; Veys, Paul; Wagner, John E.; Savani, Bipin N.; Hamadani, Mehdi; and
MoffittVerneris,
Cancer Center
Carpenter, Paul A., "Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft
Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell
See
next page for additional
Transplantation:
A Report authors
on Behalf of the American Society for Transplantation and Cellular
Therapy." (2021). Department of Medical Oncology Faculty Papers. Paper 148.
https://jdc.jefferson.edu/medoncfp/148
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors
Mohamed A. Kharfan-Dabaja, Ambuj Kumar, Ernesto Ayala, Mahmoud Aljurf, Taiga Nishihori, Rebecca
Marsh, Lauri M. Burroughs, Navneet Majhail, A. Samer Al-Homsi, Zaid S. Al-Kadhimi, Merav Bar, Alice
Bertaina, Jaap J. Boelens, Richard Champlin, Sonali Chaudhury, Zachariah DeFilipp, Bhagirathbhai
Dholaria, Areej El-Jawahri, Suzanne Fanning, Ellen Fraint, Usama Gergis, Sergio Giralt, Betty K. Hamilton,
Shahrukh K. Hashmi, Biljana Horn, Yoshihiro Inamoto, David A. Jacobsohn, Tania Jain, Laura Johnston,
Abraham S. Kanate, Ankit Kansagra, Adetola Kassim, Leslie S. Kean, Carrie L. Kitko, Jessica Knight-Perry,
Joanne Kurtzberg, Hien Liu, Margaret L. MacMillan, Zahra Mahmoudjafari, Marco Mielcarek, Mohamad
Mohty, Arnon Nagler, Eneida Nemecek, Timothy S. Olson, Betul Oran, Miguel-Angel Perales, Susan E.
Prockop, Michael A. Pulsipher, Iskra Pusic, Marcie L. Riches, Cesar Rodriguez, Rizwan Romee, Gabriela
Rondon, Ayman Saad, Nina Shah, Peter J. Shaw, Shalini Shenoy, Jorge Sierra, Julie Talano, Michael R.
Verneris, Paul Veys, John E. Wagner, Bipin N. Savani, Mehdi Hamadani, and Paul A. Carpenter

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medoncfp/148

Transplantation and Cellular Therapy 27 (2021) 642649

Transplantation and
Cellular Therapy
journal homepage: www.tctjournal.org

Guideline

Standardizing Deﬁnitions of Hematopoietic Recovery, Graft Rejection,
Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic
Hematopoietic Cell Transplantation: A Report on Behalf of the
American Society for Transplantation and Cellular Therapy
Mohamed A. Kharfan-Dabaja1,*, Ambuj Kumar2, Ernesto Ayala1, Mahmoud Aljurf3, Taiga Nishihori4,
Rebecca Marsh5, Lauri M. Burroughs6, Navneet Majhail7, A. Samer Al-Homsi8, Zaid S. Al-Kadhimi9,
Merav Bar6, Alice Bertaina10, Jaap J. Boelens11, Richard Champlin12, Sonali Chaudhury13,
Zachariah DeFilipp14, Bhagirathbhai Dholaria15, Areej El-Jawahri14, Suzanne Fanning16,
Ellen Fraint11, Usama Gergis17, Sergio Giralt18, Betty K. Hamilton7, Shahrukh K. Hashmi19,20,
Biljana Horn21, Yoshihiro Inamoto22, David A Jacobsohn23, Tania Jain24, Laura Johnston25,
Abraham S. Kanate26, Ankit Kansagra27, Adetola Kassim15, Leslie S. Kean28, Carrie L. Kitko29,
Jessica Knight-Perry30, Joanne Kurtzberg31, Hien Liu4, Margaret L. MacMillan32,
Zahra Mahmoudjafari33, Marco Mielcarek6, Mohamad Mohty34, Arnon Nagler35, Eneida Nemecek36,
Timothy S. Olson37, Betul Oran12, Miguel-Angel Perales18, Susan E. Prockop11,
Michael A. Pulsipher38, Iskra Pusic39, Marcie L. Riches40, Cesar Rodriguez41, Rizwan Romee42,
Gabriela Rondon12, Ayman Saad43, Nina Shah44, Peter J. Shaw45, Shalini Shenoy46, Jorge Sierra47,
Julie Talano48, Michael R. Verneris30, Paul Veys49, John E. Wagner32, Bipin N. Savani15,
Mehdi Hamadani50, Paul A. Carpenter6
1

Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program, Mayo Clinic, Jacksonville, Florida
Program for Comparative Effectiveness Research, Morsani College of Medicine, University of South Florida, Tampa, Florida
3
Department of Adult Hematology and Stem Cell Transplantation, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
4
Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Mofﬁtt Cancer Center, Tampa, Florida
5
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
6
Fred Hutchinson Cancer Research Center, Seattle, Washington
7
Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio
8
NYU Langone Health, New York, New York
9
Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
10
Division of Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California
11
Stem Cell Transplantation and Cellular Therapies Program, Department Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
12
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
13
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
14
Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, Massachusetts
15
Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
16
Blood and Marrow Transplant Program, University of South Carolina School of Medicine, Greenville, South Carolina
17
Bone Marrow Transplant and Immune Cellular Therapy, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
18
Department of Medicine, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center Weill Cornell Medical College, New York, New York
19
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
20
Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates
21
Department of Pediatrics, Division of Hematology/Oncology, University of Florida, UF Health Shands Children's Hospital, Gainesville, Florida
22
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
23
Division of Blood and Marrow Transplantation Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC
24
Hematologic Malignancies and Bone Marrow Transplantation Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine,
Baltimore, Maryland
25
Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, California
26
West Virginia University, Morgantown, West Virginia
27
UT Southwestern Medical Center, Dallas, Texas
2

Financial disclosure: See Acknowledgments on page 648.
*Correspondence and reprint requests: Mohamed A. Kharfan-Dabaja, MD, MBA, FACP, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224.
E-mail address: KharfanDabaja.Mohamed@mayo.edu (M.A. Kharfan-Dabaja).

https://doi.org/10.1016/j.jtct.2021.04.007
2666-6367/© 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

M.A. Kharfan-Dabaja et al. / Transplantation and Cellular Therapy 27 (2021) 642649

643

28

Boston Children's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts
Division of Pediatric Hematology/Oncology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
30
Department of Pediatrics, Division of Hematology/Oncology/BMT, University of Colorado School of Medicine, Aurora, Colorado
31
Pediatric Blood and Marrow Transplant Program, Duke University School of Medicine, Durham, North Carolina
32
Blood and Marrow Transplant Program, Masonic Cancer Center, University of Minnesota Medical School, Minneapolis, Minneapolis
33
Division of Pharmacy, University of Kansas Cancer Center, University of Kansas Health System, Lawrence, Kansas
34
^pital Saint-Antoine, Service d'Hematologie Clinique et Therapie Cellulaire, Paris, France
Sorbonne Universite, INSERM, Centre de Recherche Saint-Antoine and Ho
35
Chaim Sheba Medical Center, Tel Hashomer, Israel
36
Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon
37
Blood and Marrow Transplant Section, Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Pennsylvania
38
Children's Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California
39
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri
40
Division of Hematology, University of North Carolina at Chapel Hill, North Carolina
41
Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina
42
Cellular Therapy and Stem Cell Transplant Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
43
Division of Hematology, The Ohio State University, Columbus, Ohio
44
Division of Hematology-Oncology, Department of Medicine, University of California San Francisco, San Francisco, California
45
The Children's Hospital at Westmead, Sydney, Australia
46
Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri
47
Department of Hematology, Hospital de la Santa Creu i Sant Pau, Josep Carreras Leukemia Research Institute, Barcelona, Spain
48
Department of Pediatric Hematology/Oncology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin
49
Blood & Marrow Transplant Unit, Great Ormond Street Hospital, University College London, London, United Kingdom
50
Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
29

Article history:
Received 11 April 2021
Accepted 11 April 2021
Key Words:
Allogeneic hematopoietic cell
transplantation
Hematopoietic recovery
Graft rejection
Graft failure
Donor chimerism

A B S T R A C T
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The ﬁeld of allo-HCT has witnessed signiﬁcant advances, including broadening
indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell
manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of
the procedure. These advances have led to clinical practice conundrums when applying traditional deﬁnitions of
hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism, because these
may vary based on donor type, cell source, cell dose, primary disease, graft-versus-host disease (GVHD) prophylaxis, and conditioning intensity, among other variables. To address these contemporary challenges, we surveyed
a panel of allo-HCT experts in an attempt to standardize these deﬁnitions. We analyzed survey responses from
adult and pediatric transplantation physicians separately. Consensus was achieved for deﬁnitions of neutrophil
and platelet recovery, graft rejection, graft failure, poor graft function, and donor chimerism, but not for delayed
engraftment. Here we highlight the complexities associated with the management of mixed donor chimerism in
malignant and nonmalignant hematologic diseases, which remains an area for future research. We recognize that
there are multiple other speciﬁc, and at times complex, clinical scenarios for which clinical management must be
individualized.
© 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is
potentially curative for certain hematologic malignancies and
nonmalignant diseases [1,2] and is now more broadly applicable owing to improved outcomes using not just HLA-matched
sibling or unrelated donors, but also umbilical cord blood and
haploidentical related donors. Increased options of reducedintensity (RIC) or nonmyeloablative (NMA) conditioning can
mitigate transplantation-related mortality in high-risk alloHCT and further expand feasibility [3-7]. More than 95% of
patients needing an allo-HCT now have access to a suitable
donor. These advances have led to clinical practice conundrums when applying traditional deﬁnitions of hematopoietic
recovery, graft rejection, and graft failure, because hematopoietic recovery and engraftment kinetics may vary based on
donor type, cell source, cell manipulation and dose, primary
disease, graft-versus-host disease (GVHD) prophylaxis, and
conditioning intensity, among other factors [8-12]. In daily
clinical practice deﬁnitions have been used interchangeably,
albeit inconsistently or incorrectly. For instance, recovery of
neutrophils, operationally deﬁned as achievement of an absolute neutrophil count (ANC) of 500 cells/mL, is at times also
used to deﬁne hematopoietic engraftment. The latter implies
that donor neutrophils have reached 500 cells/mL, which might

not be true in the case of primary graft failure with autologous
neutrophil recovery. Moreover, in NMA conditioning, especially for nonmalignant diseases, engraftment deﬁnitions
based only on neutrophil recovery but agnostic of chimerism
are insufﬁcient to address late graft failure, because neutrophil
recovery might occur with complete loss of donor chimerism.
Contemporary allo-HCT practice measures the level of
donor chimerism by quantifying the percentage of unsorted
marrow and/or microﬂuorimetrically sorted peripheral blood
leukocytes. Leukocyte compartments most commonly evaluated include granulocytes (via CD33 surface expression) and T
cells (CD3), sometimes extending to B cells (CD19) and natural
killer cells (CD56), depending on the disease indication for
allo-HCT. Full donor chimerism is most commonly deﬁned
empirically using a cutoff of >90%, >95%, or >97.5%. Partial,
more commonly known as mixed, donor chimerism has been
deﬁned empirically using lower-end cutoffs such as >2.5% up
to >10% and upper-end cutoffs such as 90% up to 97.5%.
Absence of donor chimerism has been empirically deﬁned by
cutoffs of <2.5%, <5%, and <10% [13]. RIC or NMA conditioning
regimens are more likely to result in mixed donor chimerism
compared with myeloablative conditioning (MAC) regimens
[14]. In the 2001 workshop, the authors recommended avoiding using a speciﬁc threshold to deﬁne mixed chimerism,
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owing to multiple factors that may potentially affect results,
including assay sensitivity, underlying disease, and cellular
compartment(s) involved; accordingly, mixed chimerism was
simply deﬁned as any reliable detection of host hematopoietic
cells, hence the wide range still used in current practice [15].
Although this is conceptually factual, certain levels of mixed
chimerism within this wide range might be considered clinically acceptable or not, depending on the underlying allo-HCT
indication. For instance, in patients who undergo allo-HCT for
sickle cell disease, a certain level of stable mixed donor myeloid chimerism is considered an acceptable endpoint for disease correction because it tracks with donor erythrocyte
chimerism. Similarly, marrow failure syndromes, like Fanconi
anemia or Diamond Blackfan anemia, are correctable with stable mixed chimerism, but anything less than full donor myeloid chimerism does not erase concerns about future (host)
myelodysplasia or acute myelogenous leukemia. After alloHCT for hematologic malignancies, it is intuitive that early,
durable full donor chimerism is desirable, because a low level
of donor chimerism is associated with an elevated risk for disease relapse [16,17].
To address these contemporary challenges, we organized a
panel of pediatric and adult allo-HCT experts to attempt to
standardize deﬁnitions of hematopoietic (neutrophil and
platelet) recovery, graft rejection, primary and secondary graft
failure, poor graft function, and donor chimerism. We conducted a survey of adult and pediatric transplantation physicians separately. Whenever applicable, we provide clinical
scenarios to highlight the application of these consensus deﬁnitions in clinical practice.

METHODS
Panel Composition
We assembled a steering committee of 14 physicians with expertise in
allo-HCT and 1 independent methodology expert with expertise in evidence
synthesis and the RAND-modiﬁed Delphi methods to develop the survey
questions. The steering committee drafted the protocol and consensus statements based on systematic review of the literature and clinical practice considerations, and set up the expert panel. The ﬁrst round of the survey
comprised 3 questions on panel demographics, 4 questions on practice setting, and 26 questions on deﬁnitions and clinical management. Considering
the differences in transplantation practices across age groups, we assembled
separate ﬁnal panels for adult (n = 25) and pediatric (n = 23) HCT physicians
with steering committee representative(s) from either panel. Panel physicians included diverse geographical representation and expertise in the ﬁeld,
as demonstrated by a track record of peer-reviewed publications, leadership
of clinical trials, and involvement in national and international transplantation societies. The methodology expert assisted with designing, developing,
and administering the surveys along with data collection and analysis, but
did not participate in the voting process at any stage.

Methodology
Before voting on recommendations, a formal guidance document on the
RAND-modiﬁed Delphi method was shared with all participants; a statement
with 70% vote in favor/against was considered a consensus. A formal evaluation of patient values and preferences and cost was not conducted; however, an overall assumption was made that recommendations would be
feasible in the setting across panel member practices and would not add any
additional burden on existing resources. The questions covered the broad
domains of deﬁnitions and clinical practice recommendations. Consistent
with the RAND-modiﬁed Delphi methodology, participants rated all statements anonymously for all rounds of voting. Furthermore, all but one rounds
of voting were administered online via Qualtrics survey management software (Qualtrics, Provo, UT). One round of the survey was administered anonymously online via Poll Everywhere (pollev.com) during the virtual meeting
aimed at reaching consensus, in lieu of an in-person meeting, owing to the
COVID-19 pandemic. Descriptive statistics was used to analyze the results of
the survey, which are summarized as proportions.

Table 1
Panel Member Demographics
Characteristic

Adult Transplantation
Physicians (n = 20)

Pediatric Transplantation
Physicians (n = 19)

Age, yr, n (%)
5-45

6 (30)

4 (21)

46-55

10 (50)

8 (42)

56-65

3 (15)

6 (32)

>65

1 (5)

1 (5)

3 (15)

10 (53)

17 (85)

9 (47)

Sex, n (%)
Female
Male
Years in practice,
n (%)
<5

1 (5)

1 (5)

5-10

3 (15)

2 (11)

11-15

7 (35)

2 (11)

16-20

5 (25)

6 (32)

>20

4 (20)

8 (42)

RESULTS
Demographics
During the initial round, 20 of the 25 invited identiﬁed
themselves as adult-treating and 19 of 23 invited identiﬁed
themselves as pediatric-treating transplantation physicians. In
the adult-treating group, the majority were male (85%), and
80% of participants had more than 10 years of experience. In
the pediatric-treating group, female physicians composed 53%
of the total participants, and 85% had more than 10 years of
experience (Table 1).
Practice Characteristics
The majority (55%) in the adult-treating group reported practicing in transplant centers that perform >100 allo-HCT procedures annually, mostly from HLA-matched unrelated donors
(MUDs) using peripheral blood stem cells as the preferred cell
source. On the other hand, the majority in the pediatric-treating
group (63%) reported practicing in centers that perform >50 alloHCT procedures annually, mostly from HLA-MUDs using bone
marrow (BM) as the preferred cell source (Table 2).
Deﬁnitions and Management Recommendations
Neutrophil and Platelet Recovery
As summarized in Table 3, both the adult and pediatric transplantation panels endorsed existing working deﬁnitions of neutrophil and platelet recovery set forth by the Center for International
Blood and Marrow Transplant Research (CIBMTR).
Delayed Engraftment, Graft Rejection, Graft Failure, Poor Graft
Function, and Secondary Graft Failure
Neither panel could reach consensus on the deﬁnition of
delayed engraftment (Table 3). However, there was consensus
on differentiating graft rejection from graft failure, deﬁning
poor graft function, and secondary graft failure. Both panels
deﬁned graft rejection as an immune-mediated process,
whereas graft failure was considered to represent a wider
array of possibilities, including cell dosing, disease, infections,
drugs, and an immune-mediated event.
There was consensus on deﬁning primary graft failure
based on different cell sources. For instance, both panels
deﬁned graft failure when using peripheral blood stem cells or
unstimulated BM as lack of achievement of an ANC 500/mL
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regimen or whether T cell-replete or T cell-depleted grafts
were prescribed (Table 4).

Table 2
Transplant Center and Practice Characteristics
Adult
Transplantation
Physicians

Pediatric
Transplantation
Physicians

<50

2 (10)

7 (37)

51-100

7 (35)

9 (47)

101-200

6 (30)

1 (5)

>200

5 (25)

2 (11)

PBSCs

20 (74)

5 (21)

Unstimulated BM

6 (22)

13 (54)

G-CSF-stimulated BM

1 (4)

0

UCB

0

4 (17)

Other

0

2 (8)y

MRD

10 (29)

7 (17)

MUD

16 (47)

15 (36)

MMRD/haploidentical

7 (21)

7 (17)

MMUD

0

6 (14)

UCB

1 (3)

7 (17)

Center Characteristics

645

Number of allo-HCTs/yr, n (%)

Cell source, n (%)*

Donor type, n (%)*

PBSCs indicates peripheral blood stem cells; UCB, umbilical cord blood; MRD,
HLA-matched related donor; MUD, HLA-matched unrelated donor; MMRD:
HLA-mismatched related donor; MMUD: HLA-mismatched unrelated donor.
* More than one option may apply/the number of responses may exceed
the number of participants.
y
Alpha-beta-depleted haploidentical transplantation (n = 1), ex vivo T celldepleted PBSCs (n = 1).

by day +30 with associated pancytopenia. When using cord
blood, both panels deﬁned graft failure as lack of achievement
of an ANC 500/mL by day +42 with associated pancytopenia.
This assumes that donor chimerism testing is also done to conﬁrm the suspicion of graft failure. There was no consensus by
either panel to deﬁne graft failure when using G-CSF-stimulated BM (Table 3).
Poor graft function was deﬁned as frequent dependence on
blood and/or platelet transfusions and/or growth factor support in the absence of other explanations, such as disease
relapse, drugs, or infection (Table 3).
Secondary graft failure was deﬁned as a decline in hematopoietic function (possibly involving hemoglobin and/or platelets and/or neutrophils) necessitating blood products or
growth factor support, after having met the standard deﬁnition of hematopoietic (neutrophil and platelet) recovery
(Table 3). Both panels recommended assessing secondary graft
failure by evaluating hematopoietic function (based on peripheral blood counts), BM cellularity, and donor chimerism
(Table 4).
Donor Chimerism
Both panels endorsed current deﬁnitions of full donor chimerism as >95%, mixed donor chimerism as 5% to 95%, and
absent donor chimerism as <5%, for both myeloid and lymphoid lineages (Table 3).
Measuring Donor Chimerism
Both panels recommended routine measurement of donor
chimerism using CD3 or similar for lymphoid cells and CD33
or similar for myeloid cells. During the ﬁrst year after alloHCT, both panels recommended routine measurement of
donor chimerism on approximately days +30, +90, and +180
and at 1 year regardless of the intensity of the preparative

Managing Mixed Donor Chimerism in Allo-HCT
Although both panels endorsed the current deﬁnition of
mixed donor chimerism as 5% to 95% for both myeloid and
lymphoid lineages, they also recognized the practical importance of using the actual percentage of donor cells for clinical
management. In this case, the panels recommended that individual patient management be based on a consideration of the
actual (downward or upward) trajectories of percent donor
myeloid and lymphoid chimerism, together with complete
blood counts and clinical status. Because trajectories can help
inform medical decision making, the panel recommends measuring donor chimerism at speciﬁc time points during the ﬁrst
year post-allo-HCT (eg, days +30, +90, +180, and +365).
Pertaining to speciﬁc management of downward trajectories in donor CD3 and CD33 chimerism in the malignant disease setting, Figure 1 highlights the complex decision-making
in real-world clinical practice. Although withdrawal (or tapering) of immune suppression appeared to be the most frequently chosen approach for declining donor chimerism, the
median response was to select 2 possible therapeutic options
(range, 1 to 5). Decision making is further complicated by
other variables, for example, did the downward donor chimerism trajectory occur in the setting of disease relapse/progression or during a continuous remission? Was GVHD present or
not? What was the ablative intensity of the conditioning regimen? Was T cell depletion part of conditioning? These are just
a few examples.
Figure 2 also highlights the complex clinical decision process associated with managing similar downtrends in donor
chimerism in the context of nonmalignant disease. Interestingly, fewer adult transplantation physicians responded to this
question relative to pediatric transplantation physicians
(n = 15 versus n = 17; Figure 2) compared with responses to
the same questions for malignant disease context (n = 19 versus n = 16; Figure 1). This may highlight the broader experience with allo-HCT for nonmalignant diseases in the pediatric
transplantation group. Both panels recognized that the level of
donor chimerism required for nonmalignant disease correction depends on the speciﬁc underlying disease indication for
transplantation; however, speciﬁc levels of donor chimerism
were not discussed for particular disease indications.
Finally, the panel could not identify a single best approach
to the management of down-trending donor chimerism in
either the malignant or the nonmalignant disease setting.
DISCUSSION
This work represents an effort to standardize deﬁnitions of
hematopoietic recovery, graft rejection, primary and secondary graft failure, poor graft function, and donor chimerism in
the setting of allo-HCT, and also to provide broad guidance on
the clinical management of mixed donor chimerism. We recognize that there are multiple other speciﬁc and at times complex clinical scenarios for which clinical management must be
individualized.
Pertaining to neutrophil and platelet recovery, both adult
and pediatric transplantation physician panels endorsed the
existing CIBMTR working deﬁnitions. Here, using the word
“recovery” instead of “engraftment” is more appropriate,
because conﬁrmation of donor source ideally requires also
proof of at least mixed/partial donor chimerism, which generally occurs later in the course of transplantation. Neither panel
reached a consensus in deﬁning a speciﬁc time point for
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Table 3
Consensus Deﬁnitions from the Adult and Pediatric Transplantation Physician Panels
Term

Deﬁnition

Neutrophil recovery

Both panels endorsed the existing deﬁnition of neutrophil recovery as the ﬁrst of 3 successive days with an absolute
neutrophil count of 500/mL after post-transplantation nadir.

Platelet recovery

Both panels endorsed the deﬁnition of platelet recovery as the ﬁrst of 3 consecutive days with a platelet count of 20,000/
mL or higher in the absence of platelet transfusion for 7 consecutive days.

Delayed engraftment

No consensus was reached by either panel.

Graft rejection versus graft failure

Both panels deﬁned graft rejection as an immune-mediated process, whereas graft failure represents a wider array of
possibilities, including cell dosing, disease, infection, drugs, and an immune-mediated event.

Graft failure (primary)*
(according to cell source)

PBSCs: Both panels deﬁned graft failure as lack of achievement of an ANC 500/mL by day +30 with associated
pancytopenia.
Unstimulated BM: Both panels deﬁned graft failure as lack of achievement of an ANC 500/mL by day +30 with associated pancytopenia.
G-CSF-stimulated BM: No consensus was reached by either panel.
UCB: Both panels deﬁned graft failure as lack of achievement of an ANC  500/mL by day +42 with associated
pancytopenia.

Poor graft function**

Both panels deﬁned poor graft function as frequent dependence on blood and/or platelet transfusions and/or growth
factor support in the absence of other explanations, such as disease relapse, drugs, or infections.

Secondary graft failure*

Both panels deﬁned secondary graft failure as a decline in hematopoietic function (may involve hemoglobin and/or platelets and/or neutrophils) necessitating blood products or growth factor support, after having met the standard deﬁnition of hematopoietic (neutrophils and platelets) recovery.

Donor chimerism

Full: Both panels endorsed the existing deﬁnition of full donor chimerism as >95% for both myeloid and lymphoid
lineages.
Mixed or partial: Both panels endorsed the existing deﬁnition of mixed donor chimerism as 5% to 95% for both myeloid
and lymphoid lineages.
Absent: Both panels endorsed the existing deﬁnition of absent donor chimerism as <5% for both myeloid and lymphoid
lineages.

PBSC, peripheral blood stem cells; ANC, absolute neutrophil count; BM, bone marrow cells; G-CSF, granulocyte colony stimulating factor.
* Donor chimerism testing is also done to conﬁrm the suspicion of graft failure.
** Assumes that donor myeloid and lymphoid chimerism are within a desirable target level.

Table 4
Recommendations of the Adult and Pediatric Transplantation Physician Panels
Category

Recommendations

Assessment of secondary graft failure

Evaluating hematopoietic function (based on peripheral blood counts), bone marrow cellularity, and donor chimerism(s) when assessing secondary graft failure

Measuring donor chimerism

Routine practice includes measurement of donor chimerism using CD3 or similar for lymphoid cells and CD33 or
similar for myeloid cells.
During the ﬁrst year after allo-HCT, measure donor chimerism routinely on days +30, +90, and +180 and at 1 year
during the ﬁrst year post- allo-HCT.
Measure sorted (CD3 and/or CD33) donor chimerism routinely in patients receiving MAC, RIC, or NMA conditioning.
Measure sorted (CD3 and/or CD33) donor chimerism routinely when using T cell-depleted grafts (in vivo or ex vivo).

Managing mixed donor
chimerism (malignant diseases)

The panel recognizes the impact of the actual percentage of donor cells for clinical management.
Consider using the actual percentages of donor myeloid cells and lymphoid cells, blood counts and the clinical status of the patient for a change in management.
Use the actual percentage of mixed donor chimerism at speciﬁc time points post-allografting (ie, days +30, +90,
+180, and +365) for a change in management.
Consider the decline from a prior chimerism level to inform clinical management.

Managing mixed donor chimerism
(nonmalignant diseases/bone marrow
failure syndromes)

The panel recognizes that the level of donor chimerism required for disease correction depends on the disease.
Consider the decline from a prior chimerism level to inform clinical management.

delayed engraftment. This is not surprising, because in theory,
delayed engraftment represents a continuum from the time of
absence of hematopoietic recovery until objective conﬁrmation of graft failure. Moreover, from a treatment standpoint,
these patients generally continue to receive supportive interventions while cytopenic, such as antimicrobial prophylaxis,
blood products, and growth factors, among others.
Guidelines differentiate between graft rejection and graft failure because they have different therapeutic implications. For graft
rejection, interventions concentrate primarily on overcoming the
HLA disparity barrier. However, interventions for graft failure are
more varied based on speciﬁc situations and might include

administering a CD34-selected cell boost to address poor graft
function with or without mixed/absent chimerism in the myeloid
compartment and prescribing donor lymphocyte infusion(s) to
treat low mixed chimerism, but do require at least 5% donor lymphoid chimerism. Other interventions to treat graft failure include
considering a second allo-HCT, treatment of infections, and withholding suspected myelotoxic drugs, among others, as clinically
indicated.
Different from graft failure, poor graft function assumes
that donor myeloid and lymphoid chimerism are within a
desirable target level and that there are other causes that
explain the continuous need for blood products or growth
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Options for down-trending
CD3 donor chimerism
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CD33 donor chimerism
Withdraw immune suppression
Increase immune suppression
Donor Lymphocyte infusion
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Second allogeneic HCT

Figure 1. Transplantation physician responses to options for managing down-trending chimerism in malignant diseases. Management responses are shown for pediatric transplantation panel members to declines in CD3 (A) and CD33 donor chimerism (C). Similar responses are shown for adult transplant panel members in (B)
and (D), respectively.
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Figure 2. Transplantation physician responses to options for managing down-trending chimerism in nonmalignant diseases. Management responses are shown for
pediatric transplantation panel members to declines in CD3 (A) and CD33 donor chimerism (C). Similar responses are shown for adult transplantation panel members
in (B) and (D), respectively.

factor support. For instance, diseases such as myeloﬁbrosis
could cause poor graft function post-transplantation, requiring
frequent transfusion of blood products during the ﬁrst few
months, even in the presence of full donor myeloid chimerism.
For primary graft failure, both panels endorsed using a
practical deﬁnition based on lack of recovery of ANC to 500/
mL in the presence of associated cytopenias at a particular time
point based on the prescribed stem cell source (Table 3). We
acknowledge that additional workup is certainly required,
which should include assessing marrow cellularity and quantifying donor chimerism levels to conﬁrm graft failure (Table 3),
and that future interventions could vary depending on several
factors, such as patient functional status and disease-speciﬁc
reasons, among others. In cases of secondary graft failure,
patients have a decline in hematopoietic function and conﬁrmation of absent donor chimerism levels after previously
documented full or mixed donor chimerism levels.
Notwithstanding the different sensitivities of donor chimerism methodologies, both panels endorsed current working
deﬁnitions of full donor chimerism in myeloid and lymphoid
lineages as >95%, mixed or partial donor chimerism as 5% to
95%, and absence of donor chimerism as <5% (Table 3).
Although both panels endorsed the deﬁnition of mixed donor
chimerism as 5% to 95%, they acknowledged several clinical

practice limitations related to this deﬁnition. Intuitively,
patients with lower levels of mixed donor chimerism are likely
to be treated differently than those with higher levels. Moreover, mixed chimerism is a dynamic state in which a progressive decline in donor chimerism might portend or conﬁrm
graft loss or disease recurrence, depending on the cell compartment analyzed. For instance, a 10% level of CD3 donor chimerism might prompt consideration for donor lymphocyte
infusion or even prescription of antineoplastic therapy in the
case of a T cell malignancy. On the other hand, an 80% donor
CD3 level, which still meets the deﬁnition of mixed donor chimerism, is more likely to be followed closely until a clearer
trend is established. Furthermore, management could be different if mixed donor chimerism is observed in only one lineage versus both lineages. We acknowledge that in the setting
of T cell depletion, ex vivo or in vivo, CD3 chimerism might be
low or absent for many months after transplantation.
When managing declining donor chimerism levels,
approaches tend to consider not only the speciﬁc lineage(s)
involved, but also the percentage decline (trajectory) over
time from a known peak level. Repeating donor chimerism levels should be considered to conﬁrm the results. When both
panels were asked about the immediate next step in managing
declines in donor CD3 and CD33 chimerism in the setting of
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allo-HCT for malignant diseases, the most frequent response
was to withdraw (or taper) immune suppression (Figure 1). In
addition, more than one-half of respondents chose more than
one possible option, underscoring the complexities associated
with managing such clinical situations. Caveats must certainly
be applied, because in certain scenarios, such as the presence
of active GVHD, withdrawing (or tapering) immune suppression might be inappropriate.
In the case of declining CD3 and CD33 donor chimerism in the
setting of nonmalignant disorders, both panels also chose withdrawing immune suppression as the next immediate step in managing a downward trend in CD3 and CD33 chimerism. Again,
more than one-half of the participants chose more than one
option. Such decisions need to consider several factors, including
but not limited to the patient's underlying disease indication for
allo-HCT, whether the downtrend occurred in the context of minimal versus heavy pretransfusion, whether the decreases in chimerism and blood counts were observed during steady-state versus
tapered immune suppression, and the intensity of the preparative
regimen (MAC versus RIC). We acknowledge that optimal management of declining donor chimerism, particularly in patients
with nonmalignant disorders, remains an area in which future
research is deﬁnitely needed.
The main goal in developing these consensus deﬁnitions
and recommendations is to harmonize allo-HCT clinical practice. These guidelines are not intended to replace clinical judgment, as there are several situations were decisions need to be
individualized.
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